Market Overview:
The global urological cancer drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of urological cancers, rising awareness about urological cancers, and technological advancements in the field of urological cancer treatments. The global market for tablets is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030, while that for injections is expected to grow at a CAGR of 6.7%.
Product Definition:
Urological cancer drugs are those that are used to treat cancers of the urinary system. This includes cancers of the bladder, prostate, and kidneys. Urological cancer drugs can be used to treat these cancers either by shrinking the tumors or by stopping their growth.
Tablets:
Tablets, it's usage.
U.S. FDA approval for the use of tablets in cancer treatment is an important driver expected to boost demand over the forecast period.?The global urological cancer drugs market was valued at USD 20 billion in 2015 and is projected to grow at a CAGR of XX% during the forecast period.
Injection:
Injection is a medical procedure used to introduce the medication into the vein. The drug is then transported through blood to reach the target tissue or organs. In Urological cancer drugs market, injections are used in treating prostate cancer and urinary bladder cancer.
The process of injecting medicine into a patient’s body can be painful depending on various factors such as muscle length, thickness,.
Application Insights:
The prostate cancer segment held the largest share of around 30.0% in 2017 owing to the increasing prevalence of this disease. According to data published by the American Cancer Society, prostate cancer is one of the most common cancers found among males aged 55 and above. In 2018, around 54,000 new cases were reported globally and over 14,000 deaths were caused due to this disease. Increasing awareness about early diagnosis and treatment is expected to boost market growth during the forecast period for urological cancer drugs involving in prostate cancer.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of modern treatment techniques and high healthcare expenditure in this region. Moreover, rising incidence rates of urological cancers are expected to fuel growth during the forecast period. Asia Pacific is expected to witness lucrative growth over the forecast period owing to increasing disposable income levels and awareness about early diagnosis among patients. In addition, government initiatives for improving healthcare facilities are also anticipated to drive regional market growth during the forecast period. Furthermore, growing medical tourism industry due to affordable treatment options is further fueling demand for urological cancer drugs in this region as a result of rapid economic development since past few years (revenue-based exchange rate).
Moreover, Latin America has also been witnessing an increase in medical tourists mainly from developed countries such as U.S.
Growth Factors:
- Increasing incidence of urological cancer
- Growing awareness about urological cancer and its treatment options
- Rising demand for better and more effective urological cancer drugs
- Technological advancements in the field of urological cancer drugs development and research 5. Availability of government funding for research on urological cancers
Scope Of The Report
Report Attributes
Report Details
Report Title
Urological Cancer Drugs Market Research Report
By Type
Tablets, Injection
By Application
Prostate Cancer, Bladder Cancer, Kidney Cancer, Testicular Cancer, Others
By Companies
Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, Novartis, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A, Tolmar Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
154
Number of Tables & Figures
108
Customization Available
Yes, the report can be customized as per your need.
Global Urological Cancer Drugs Market Report Segments:
The global Urological Cancer Drugs market is segmented on the basis of:
Types
Tablets, Injection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Prostate Cancer, Bladder Cancer, Kidney Cancer, Testicular Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Pfizer
- Johnson & Johnson
- AstraZeneca
- Astellas
- Bristol-Myers Squibb
- Abbott Laboratories
- Celgene Corporation
- Dendreon Corporation
- Ferring Pharmaceuticals
- Novartis
- Indevus Pharmaceuticals Inc
- Ipsen
- Roche Healthcare
- Sanofi S.A
- Tolmar Inc
Highlights of The Urological Cancer Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablets
- Injection
- By Application:
- Prostate Cancer
- Bladder Cancer
- Kidney Cancer
- Testicular Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Urological Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Urological cancer drugs are medications used to treat cancer of the urinary tract. These medications can help to shrink or stop the growth of tumors in the urinary tract, and may also help to prevent further damage to the bladder and urethra.
Some of the major players in the urological cancer drugs market are Novartis, Pfizer, Johnson & Johnson, AstraZeneca, Astellas, Bristol-Myers Squibb, Abbott Laboratories, Celgene Corporation, Dendreon Corporation, Ferring Pharmaceuticals, Novartis, Indevus Pharmaceuticals Inc, Ipsen, Roche Healthcare, Sanofi S.A, Tolmar Inc.
The urological cancer drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Urological Cancer Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Urological Cancer Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Urological Cancer Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Urological Cancer Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Urological Cancer Drugs Market Size & Forecast, 2018-2028
4.5.1 Urological Cancer Drugs Market Size and Y-o-Y Growth
4.5.2 Urological Cancer Drugs Market Absolute $ Opportunity
Chapter 5 Global Urological Cancer Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Urological Cancer Drugs Market Size Forecast by Type
5.2.1 Tablets
5.2.2 Injection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Urological Cancer Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Urological Cancer Drugs Market Size Forecast by Applications
6.2.1 Prostate Cancer
6.2.2 Bladder Cancer
6.2.3 Kidney Cancer
6.2.4 Testicular Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Urological Cancer Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Urological Cancer Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Urological Cancer Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Urological Cancer Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Urological Cancer Drugs Market Size Forecast by Type
9.6.1 Tablets
9.6.2 Injection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Urological Cancer Drugs Market Size Forecast by Applications
9.10.1 Prostate Cancer
9.10.2 Bladder Cancer
9.10.3 Kidney Cancer
9.10.4 Testicular Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Urological Cancer Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Urological Cancer Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Urological Cancer Drugs Market Size Forecast by Type
10.6.1 Tablets
10.6.2 Injection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Urological Cancer Drugs Market Size Forecast by Applications
10.10.1 Prostate Cancer
10.10.2 Bladder Cancer
10.10.3 Kidney Cancer
10.10.4 Testicular Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Urological Cancer Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Urological Cancer Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Urological Cancer Drugs Market Size Forecast by Type
11.6.1 Tablets
11.6.2 Injection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Urological Cancer Drugs Market Size Forecast by Applications
11.10.1 Prostate Cancer
11.10.2 Bladder Cancer
11.10.3 Kidney Cancer
11.10.4 Testicular Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Urological Cancer Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Urological Cancer Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Urological Cancer Drugs Market Size Forecast by Type
12.6.1 Tablets
12.6.2 Injection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Urological Cancer Drugs Market Size Forecast by Applications
12.10.1 Prostate Cancer
12.10.2 Bladder Cancer
12.10.3 Kidney Cancer
12.10.4 Testicular Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Urological Cancer Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Urological Cancer Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Urological Cancer Drugs Market Size Forecast by Type
13.6.1 Tablets
13.6.2 Injection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Urological Cancer Drugs Market Size Forecast by Applications
13.10.1 Prostate Cancer
13.10.2 Bladder Cancer
13.10.3 Kidney Cancer
13.10.4 Testicular Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Urological Cancer Drugs Market: Competitive Dashboard
14.2 Global Urological Cancer Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Pfizer
14.3.3 Johnson & Johnson
14.3.4 AstraZeneca
14.3.5 Astellas
14.3.6 Bristol-Myers Squibb
14.3.7 Abbott Laboratories
14.3.8 Celgene Corporation
14.3.9 Dendreon Corporation
14.3.10 Ferring Pharmaceuticals
14.3.11 Novartis
14.3.12 Indevus Pharmaceuticals Inc
14.3.13 Ipsen
14.3.14 Roche Healthcare
14.3.15 Sanofi S.A
14.3.16 Tolmar Inc
